BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24240679)

  • 21. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
    Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F
    Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.
    Corbin AS; Agarwal A; Loriaux M; Cortes J; Deininger MW; Druker BJ
    J Clin Invest; 2011 Jan; 121(1):396-409. PubMed ID: 21157039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice.
    Grisolano JL; O'Neal J; Cain J; Tomasson MH
    Proc Natl Acad Sci U S A; 2003 Aug; 100(16):9506-11. PubMed ID: 12881486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia.
    Zhu J; Zhou L; Wu G; Konig H; Lin X; Li G; Qiu XL; Chen CF; Hu CM; Goldblatt E; Bhatia R; Chamberlin AR; Chen PL; Lee WH
    EMBO Mol Med; 2013 Mar; 5(3):353-65. PubMed ID: 23341130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deregulation of the Wilms' tumour gene 1 protein (WT1) by BCR/ABL1 mediates resistance to imatinib in human leukaemia cells.
    Svensson E; Vidovic K; Lassen C; Richter J; Olofsson T; Fioretos T; Gullberg U
    Leukemia; 2007 Dec; 21(12):2485-94. PubMed ID: 17728783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent advances in Philadelphia chromosome-positive malignancies: the potential role of arsenic trioxide.
    O'Dwyer ME; La Rosée P; Nimmanapalli R; Bhalla KN; Druker BJ
    Semin Hematol; 2002 Apr; 39(2 Suppl 1):18-21. PubMed ID: 12012318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.
    Cools J; Stover EH; Boulton CL; Gotlib J; Legare RD; Amaral SM; Curley DP; Duclos N; Rowan R; Kutok JL; Lee BH; Williams IR; Coutre SE; Stone RM; DeAngelo DJ; Marynen P; Manley PW; Meyer T; Fabbro D; Neuberg D; Weisberg E; Griffin JD; Gilliland DG
    Cancer Cell; 2003 May; 3(5):459-69. PubMed ID: 12781364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias.
    Tobin LA; Robert C; Rapoport AP; Gojo I; Baer MR; Tomkinson AE; Rassool FV
    Oncogene; 2013 Apr; 32(14):1784-93. PubMed ID: 22641215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells.
    Casetti L; Martin-Lannerée S; Najjar I; Plo I; Augé S; Roy L; Chomel JC; Lauret E; Turhan AG; Dusanter-Fourt I
    Cancer Res; 2013 Apr; 73(7):2052-8. PubMed ID: 23400594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.
    Roche-Lestienne C; Deluche L; Corm S; Tigaud I; Joha S; Philippe N; Geffroy S; Laï JL; Nicolini FE; Preudhomme C;
    Blood; 2008 Apr; 111(7):3735-41. PubMed ID: 18202228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor imatinib does not impair engraftment of human CD133+ cells into NOD/SCIDbeta2mNull mice.
    Pirson L; Baron F; Meuris N; Giet O; Castermans E; Greimers R; Di Stefano I; Gothot A; Beguin Y
    Stem Cells; 2006 Jul; 24(7):1814-21. PubMed ID: 16614006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role for the proapoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT-dependent gastrointestinal stromal tumor cell line.
    Gordon PM; Fisher DE
    J Biol Chem; 2010 May; 285(19):14109-14. PubMed ID: 20231287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma.
    Calipel A; Landreville S; De La Fouchardière A; Mascarelli F; Rivoire M; Penel N; Mouriaux F
    Clin Exp Metastasis; 2014 Jun; 31(5):553-64. PubMed ID: 24652072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.
    Zhang WW; Cortes JE; Yao H; Zhang L; Reddy NG; Jabbour E; Kantarjian HM; Jones D
    J Clin Oncol; 2009 Aug; 27(22):3642-9. PubMed ID: 19506164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.
    Braziel RM; Launder TM; Druker BJ; Olson SB; Magenis RE; Mauro MJ; Sawyers CL; Paquette RL; O'Dwyer ME
    Blood; 2002 Jul; 100(2):435-41. PubMed ID: 12091333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.
    Borgo C; Cesaro L; Salizzato V; Ruzzene M; Massimino ML; Pinna LA; Donella-Deana A
    Mol Oncol; 2013 Dec; 7(6):1103-15. PubMed ID: 24012109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
    Chu S; Holtz M; Gupta M; Bhatia R
    Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
    Dai Y; Rahmani M; Corey SJ; Dent P; Grant S
    J Biol Chem; 2004 Aug; 279(33):34227-39. PubMed ID: 15175350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate.
    Zhang B; Strauss AC; Chu S; Li M; Ho Y; Shiang KD; Snyder DS; Huettner CS; Shultz L; Holyoake T; Bhatia R
    Cancer Cell; 2010 May; 17(5):427-42. PubMed ID: 20478526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD117 (c-kit) expression on CD34+ cells participates in the cytogenetic response to imatinib in patients with chronic myeloid leukemia in the first chronic phase.
    Dybko J; Haus O; Jazwiec B; Urbaniak J; Wozniak M; Kaczmar-Dybko A; Urbaniak-Kujda D; Kapelko-Slowik K; Kuliczkowski K
    Acta Haematol; 2014; 132(2):166-71. PubMed ID: 24577437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.